DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C. and DENVER, April 25, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
Parexel has struck a new deal with Palantir Technologies to integrate its artificial intelligence systems into Parexel's clinical trial operations.
DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C. and TOKYO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Goldman Sachs™ Partner, Global co-Head of Private Equity Michael Bruun joins as new Director, succeeding current Goldman Sachs Board member Jo Natauri who is retiring from the firm at the end of the...
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials